Repligen Corporation to Present at Upcoming May Investor Conferences
07 Maio 2024 - 8:30AM
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused
on bioprocessing technology leadership, today announced that it
will be participating at the following May investor conferences.
- RBC Capital Markets’ 2024 Global
Healthcare Conference, being held in New York on May 14-15. Jason
K. Garland, Chief Financial Officer, is scheduled to participate in
an analyst-led discussion on May 14, 2024 at 10:30 a.m. ET, in
addition to a series of one-on-one meetings with investors.
- Craig-Hallum’s 21st Annual
Institutional Investor Conference, being held in Minneapolis on May
29. Jason K. Garland, Chief Financial officer will participate in a
series of one-on-one meetings with investors.
- Leerink Partners’ 2024
Healthcare Crossroads Conference, being held in Austin, Texas on
May 28-29. Jason K. Garland, Chief Financial Officer, is scheduled
to participate in an analyst-led discussion on May 30, 2024 at 8:40
a.m. CT, in addition to a series of one-on-one meetings with
investors.
A live webcast of the RBC and Leerink conference presentations
will be accessible through Repligen’s Investor Relations
website at www.repligen.com, and will be available for replay for a
limited period of time following the event.
About Repligen CorporationRepligen
Corporation is a global life sciences company that develops and
commercializes highly innovative bioprocessing technologies and
systems that enable efficiencies in the process of manufacturing
biological drugs. We are “inspiring advances in bioprocessing” for
the customers we serve; primarily biopharmaceutical drug developers
and contract development and manufacturing organizations (CDMOs)
worldwide. Our focus areas are Filtration and Fluid Management,
Chromatography, Process Analytics and Proteins. Our corporate
headquarters are located in Waltham, Massachusetts, and the
majority of our manufacturing sites are in the U.S., with
additional key sites in Estonia, France, Germany, Ireland, the
Netherlands and Sweden. For more information about the company see
our website at www.repligen.com, and follow us on LinkedIn.
Repligen Contact: Sondra S. NewmanGlobal Head
of Investor Relations(781) 419-1881investors@repligen.com
Repligen (NASDAQ:RGEN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Repligen (NASDAQ:RGEN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024